The regimen consisting of carboplatin and paclitaxel represents the backbone of ovarian cancer treatment. Here, we reflect on our experience administering the carboplatin/paclitaxel regimen to scores of ovarian cancer patients over the past decade and a half.
The intratumoral vasculature of high-grade serous ovarian cancer does not appear to undergo significant changes during disease progression.
Recent use of aspirin or NSAIDs is associated with improved ovarian cancer–specific survival.
MGH Program Supports Sexual Health of Women Receiving Pelvic RT for Gastrointestinal and Gynecologic Malignancies
In an interview with Cancer Network, Lorraine Drapek describes a multidisciplinary program at MGH to support vaginal and sexual health post RT for GI and gynecologic malignancies.
The approval of PARP inhibitors has caused a paradigm shift in ovarian cancer management and a challenge for clinicians, who must decide how best to use these agents in individualized treatment.
In women with ovarian cancer, those with early life adversity and anxiety had more dysregulation of cortisol, suggesting they may be at risk for more negative outcomes.
New data suggest adding bevacizumab to chemotherapy may prolong PFS in patients with recurrent ovarian cancer.
The noninferiority of neoadjuvant chemotherapy vs upfront surgery could not be confirmed with regard to overall survival in patients with ovarian, tubal, and peritoneal cancers.
A secondary cytoreductive surgery along with chemotherapy following recurrence in patients with epithelial ovarian cancer offered improved outcomes over treatment with chemotherapy alone.
Trabectedin plus pegylated liposomal doxorubicin offered clinical benefit in a real-life setting of patients with previously treated platinum-sensitive recurrent ovarian cancer.